A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
A phase 3 trial of Orelabrutinib, Bendamustine, Rituximab in mantle cell lymphoma, run by InnoCare Pharma Inc., now recruiting.
Overview
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL is a phase 3 interventional study registered as NCT06363994 by InnoCare Pharma Inc., with 476 participants planned, started 2024-05-29 and due to reach its primary completion in 2031-06-25. Interventions recorded: Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo. Conditions listed: Mantle Cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Bendamustine, Mantle cell lymphoma, Rituximab.
- TrialEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Shares Orelabrutinib, Rituximab.
- TrialA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl
Shares Bendamustine, Mantle cell lymphoma, Rituximab.
- TreatmentICP-248
Shares InnoCare Pharma, Mantle cell lymphoma.
- CompanySymBio Pharmaceuticals
Shares Bendamustine, Mantle cell lymphoma.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Bendamustine, Rituximab.
- TrialA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Shares Bendamustine, Rituximab.
- TrialA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Shares Mantle cell lymphoma, Rituximab.